Table 1. Characteristics of the patients and tumours.
| N=57 (%) | |
|---|---|
|
Sex | |
| Male | 27 (47) |
| Female | 30 (53) |
| Age (years; median (range)) | 59.9 (35–92) |
|
ECOG-PS | |
| 0 | 9 (16) |
| 1 | 36 (63) |
| 2 | 12 (21) |
|
Pancreatic tumour location | |
| Head | 32 (56) |
| Body | 14 (25) |
| Tail | 9 (16) |
| Body and tail | 2 (4) |
|
Metastatic sites | |
| Liver – (exclusive) | 41 (72) – (21 (37)) |
| Peritoneum | 21 (37) |
| Lung | 11 (19) |
| Distant lymph nodes | 6 (11) |
| Bone | 2 (4) |
| Pleura | 2 (4) |
|
Number of metastatic sites | |
| 1 | 36 (63) |
| 2 | 16 (28) |
| ⩾3 | 5 (9) |
| Biliary stent | 17 (29%) |
| First-line chemotherapy | Folfirinox |
| Number of first-line chemotherapy cycles, median (range) | 12 (1–40) |
|
First-line treatment efficacy | |
| Complete response | 0 (0) |
| Partial response | 22 (39) |
| Stable disease | 18 (32) |
| Progressive disease | 16 (28) |
| Unknown | 1 (1) |
|
First-line treatment interruption for | |
| Progression | 54 (95) |
| Toxicity | 3 (5) |
| Other | 0 (0) |
|
Oxaliplatin neurotoxicity | |
| Yes | 9 (16) |
| No | 48 (84) |
Abbrevation: ECOG-PS=Eastern Cooperative Oncology Group performance status.